Mabwell has established an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation. The international standard drug discovery platforms and skillful & efficient development platforms enable us to develop innovative biologics efficiently and submit IND rapidly. We focus on large-scale, fast-growing therapeutic areas including auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Mabwell has 14 pipeline products. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects.
Compliant with GMP requirements in China, U.S., and Europe
Integrated production capacity of monoclonal antibodies, fusion proteins, ADCs and other drug molecules to support clinical research and commercial manufacturing
53,400㎡ (13 Acres)
Capable of providing drug samples for pre-clinical & early phase clinical use (200L, antibody production; 500g, ADC production)
Scaling up production in the kilogram can meet the production needs of critical clinical to commercialization
QA & QC capabilities (under construction)
Capable of trial production
Capacity: 8,000L, antibody production; 4,000L, recombinant protein production
Have passed EU QP Audit
69,700 ㎡ (17 Acres)
Over 27,000L capacity
Distributed Control System greatly improves the automation of liquid preparation process
Full-automatic 3D warehouse to meet smart inventory management
The integration of automation and informatization to achieve digitalization
Trial production of 2 drug substance lines (6*2,000L) + 1 drug product filling line will be carried out soon
